Elevated CCL17 levels in IPF patients and mice with bleomycin-induced pulmonary fibrosis (PF) indicate that the antibody-mediated CCL17 blockade protects against fibrosis [189]. This evidence concerns the gene CCL17 and idiopathic interstitial pneumonia.